Arsenic Trioxide: all 118 studies that test it
Page 1 of 2. Open to participants first (14), then studies with results posted, then the rest; newest registration first within each.
- Arsenic Trioxide Combined With Chemotherapy for Relapsed SHH-Activated and/or TP53-Mutant MedulloblastomaNot yet recruitingNCT07856069Phase 2
- Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic SyndromeNot yet recruitingNCT07737769Phase 1
- ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.Not yet recruitingNCT07348107Phase 1
- A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)Not yet recruitingNCT07296445Phase 3
- Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M NeuroblastomaRecruitingNCT06933394Phase 2
- Oral-ATO for TP53-mutated Myeloid MalignanciesRecruitingNCT06778187Phase 2
- Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)RecruitingNCT06670222Phase 1
- Evaluate the Efficacy and Safety of Interferon-α Combined With ATO in the Treatment of Arsenic-resistant APLRecruitingNCT06450145Not applicable
- Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric CancerRecruitingNCT06088030Phase 2
- Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APLRecruitingNCT05497310Phase 1/2
- Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian CancerRecruitingNCT04518501Phase 1/2
- The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cARTRecruitingNCT03980665Phase 1
- Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid LeukemiaEnrolling by invitationNCT03031249Phase 1/2
- Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic LeukemiaRecruitingNCT01409161Phase 2
- Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M NeuroblastomaActive, not recruitingNCT03503864Phase 2Results posted
- Treatment of Chronic Graft Versus Host Disease With Arsenic TrioxideCompletedNCT02966301Phase 2Results posted
- Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic LeukemiaActive, not recruitingNCT02339740Phase 3Results posted
- Arsenic Trioxide in Treating Patients With Basal Cell CarcinomaCompletedNCT01791894Phase 1/2Results posted
- Study of Arsenic Trioxide in Small Cell Lung CancerCompletedNCT01470248Phase 2Results posted
- Low Dose Arsenic Trioxide as a Potential Chemotherapy ProtectorCompletedNCT01428128Phase 2Results posted
- Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission TherapyCompletedNCT01404949Phase 2Results posted
- Trisenox® in Women With Metastatic Endometrial CancerTerminatedNCT01184053Phase 2Results posted
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic LeukemiaCompletedNCT00866918Phase 3Results posted
- Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma PatientsCompletedNCT00661544Phase 1/2Results posted
- Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic SyndromeCompletedNCT00621023Phase 2Results posted
- A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the LiverTerminatedNCT00582400Phase 2Results posted
- S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic LeukemiaCompletedNCT00551460Phase 2Results posted
- Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic LeukemiaTerminatedNCT00528450Phase 2Results posted
- Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid LeukemiaTerminatedNCT00513305Phase 3Results posted
- Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic SyndromesCompletedNCT00274781Phase 2Results posted
- Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous LeukemiaTerminatedNCT00184054Phase 2Results posted
- Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid TumorsCompletedNCT00024258Phase 2Results posted
- Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic LeukemiaActive, not recruitingNCT07187505Not applicable
- Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic LeukemiaCompletedNCT06882031Phase 1
- Efficacy, Tolerability and Safety of Intravenous D-VC With ATO in Patients With Advanced/Metastatic Colorectal CancerStatus unknownNCT05721872Phase 1/2
- A Study for Oral SY-2101 for Participants With Acute Promyelocytic LeukemiaSuspendedNCT04996030Phase 1
- Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 MutationStatus unknownNCT04869475Phase 2
- Arsenic Trioxide for Structural p53 MutationsStatus unknownNCT04695223Phase 2
- Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 MutationStatus unknownNCT04489706Not applicable
- Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDSStatus unknownNCT03855371Phase 1
- Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic LeukaemiaStatus unknownNCT03624270Phase 2
- Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 MutationsStatus unknownNCT03381781Phase 2
- Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS)WithdrawnNCT03377725Phase 3
- Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) PatientsStatus unknownNCT02956772Phase 2
- Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell CancerWithdrawnNCT02699723Early Phase 1
- Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic LeukemiaCompletedNCT02688140Phase 3
- Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKIStatus unknownNCT02066870Phase 1
- Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular CarcinomaStatus unknownNCT01861912Phase 2/3
- Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnNCT01835288Phase 2
- Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC)TerminatedNCT01738360Phase 2
- Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)TerminatedNCT01397734Phase 1
- Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With MyelofibrosisTerminatedNCT01014546Phase 1
- Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic LeukemiaTerminatedNCT00985530Phase 1
- Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic TrioxideCompletedNCT00850304Phase 2
- Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade GliomaCompletedNCT00720564Phase 1
- Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid LeukemiaCompletedNCT00671697Phase 1
- New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic LeukemiaWithdrawnNCT00670150Phase 2
- Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT00590603Phase 1
- Pilot Trial of Arsenic + Cytarabine in Patients With MyelofibrosisCompletedNCT00572065Early Phase 1
- Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic TherapyTerminatedNCT00571116Phase 1
- Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)CompletedNCT00504764Phase 4
- Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple MyelomaWithdrawnNCT00504101Phase 1
- Phase III Trial in Acute Promyelocytic Leukemia PatientsCompletedNCT00482833Phase 3
- Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to TreatmentCompletedNCT00449137Phase 1
- Combination Chemotherapy in Treating Patients With Acute Promyelocytic LeukemiaCompletedNCT00276601Phase 2
- Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By SurgeryStatus unknownNCT00275067Phase 1/2
- Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative DisorderCompletedNCT00274820Phase 2
- Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell LeukemiaCompletedNCT00258245Phase 1
- A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic SyndromeTerminatedNCT00251511Phase 2
- A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail GleevecCompletedNCT00250042Phase 2
- Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic SyndromesTerminatedNCT00234000Phase 1
- Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00227682Phase 2
- Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS)TerminatedNCT00225992Phase 2
- Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple MyelomaCompletedNCT00201695Phase 2
- Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With ArsenicStatus unknownNCT00196768Phase 4
- Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AMLCompletedNCT00195104Phase 1/2
- Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple MyelomaCompletedNCT00193544Phase 2
- Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT00193518Phase 2
- Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant GliomaCompletedNCT00185861Phase 1
- Arsenic Trioxide in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by SurgeryCompletedNCT00128596Phase 2
- Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple MyelomaCompletedNCT00124605Phase 1
- Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic LeukemiaTerminatedNCT00118196Phase 2
- Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple MyelomaWithdrawnNCT00112879Phase 2
- Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic SyndromesTerminatedNCT00104806Phase 2
- Arsenic Trioxide and Radiation Therapy in Treating Young Patients With Newly Diagnosed GliomasCompletedNCT00095771Phase 1
- Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00093483Phase 1
- Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic SyndromesCompletedNCT00093366Phase 1/2
- Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple MyelomaWithdrawnNCT00085345Phase 2
- Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaCompletedNCT00081133Phase 1/2
- Arsenic Trioxide in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT00075426Phase 2
- Arsenic Trioxide in Treating Women With Locally Advanced or Metastatic Breast CancerWithdrawnNCT00075413Phase 2
- Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal JunctionTerminatedNCT00061958Phase 2
- Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00053248Phase 1/2
- Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to GemcitabineCompletedNCT00053222Phase 2
- Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant GliomaCompletedNCT00045565Phase 1
- Arsenic Trioxide in Treating Men With Germ Cell CancerCompletedNCT00036842Phase 2
- Arsenic Trioxide in Treating Patients With Myelodysplastic SyndromesTerminatedNCT00020969Phase 2
- Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or LymphomaCompletedNCT00020111Phase 1
- Arsenic Trioxide in Treating Patients With Multiple MyelomaTerminatedNCT00017433Phase 2
- Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple MyelomaTerminatedNCT00017069Phase 2